Jointown Pharmaceutical Group Yönetim

Yönetim kriter kontrolleri 4/4

Jointown Pharmaceutical Group CEO'su Wei He, May2022 tarihinde atandı, in görev süresi 2.5 yıldır. şirketin hisselerinin 0.005% doğrudan sahiptir ve bu hisselerin değeri CN¥ 1.43M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.1 yıl ve 4 yıldır.

Anahtar bilgiler

Wei He

İcra Kurulu Başkanı

CN¥603.1k

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	2.5yrs
CEO sahipliği	0.005%
Yönetim ortalama görev süresi	3.1yrs
Yönetim Kurulu ortalama görev süresi	4yrs

Son yönetim güncellemeleri

Recent updates

CEO

Wei He (38 yo)

2.5yrs

Görev süresi

CN¥603,100

Tazminat

Mr. Wei He has been General Manager of Jointown Pharmaceutical Group Co., Ltd since April 23, 2022 and has been its Director since May 2022.

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Wei He	GM & Director	2.5yrs	CN¥603.10k	0.0055% CN¥ 1.4m
Lei Guo	Deputy General Manager	no data	CN¥423.20k	0.018% CN¥ 4.7m
Liu Zhifeng	Deputy GM & Secretary of the Board of Directors	2.6yrs	CN¥354.60k	Veri yok
Qi Bing Wang	Deputy General Manager	no data	CN¥1.57m	0.0057% CN¥ 1.5m
Ming Quan	Deputy General Manager	no data	CN¥810.00k	Veri yok
Qingsong Zhang	Deputy General Manager	no data	CN¥382.20k	0.00027% CN¥ 70.7k
Jinghan Liu	Deputy General Manager	3.8yrs	CN¥710.00k	Veri yok
Nie Yang	Deputy General Manager	3.6yrs	CN¥443.40k	0.0052% CN¥ 1.4m
Weijun Chen	Deputy General Manager	no data	CN¥515.50k	Veri yok
Baolin Liu	Founder & Honorary Chairman	no data	CN¥881.50k	Veri yok
Ju Mei Yang	Deputy General Manager	no data	CN¥441.80k	0.014% CN¥ 3.6m
Zhang Xi	Securities Affairs Representative	no data	Veri yok	Veri yok

3.1yrs

Ortalama Görev Süresi

44yo

Ortalama Yaş

Deneyimli Yönetim: 600998 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.1 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Wei He	GM & Director	2.5yrs	CN¥603.10k	0.0055% CN¥ 1.4m
Baolin Liu	Founder & Honorary Chairman	no data	CN¥881.50k	Veri yok
Guliang Tang	Independent Director	no data	CN¥195.80k	Veri yok
Xiangquan Zeng	Independent Director	no data	CN¥150.00k	Veri yok
Shulin Liu	Emeritus Vice Chairman	1.2yrs	CN¥612.40k	1.44% CN¥ 377.5m
Zhao Nian Liu	Vice Chairman	10yrs	CN¥823.80k	1.23% CN¥ 322.1m
Qi Wang	Director	10yrs	Veri yok	Veri yok
Yihua Gong	Vice Chairman	10yrs	CN¥825.60k	0.074% CN¥ 19.3m
Ying Zheng Xu	Chairman of Supervisory Board	less than a year	CN¥722.40k	0.0017% CN¥ 452.9k
Deng Pan Liu	Vice Chairman	4yrs	CN¥823.60k	Veri yok
Hua Ai	Independent Director	no data	CN¥150.00k	0.00011% CN¥ 28.8k
Chang Yun Liu	Chairman	4yrs	CN¥1.21m	Veri yok

4.0yrs

Ortalama Görev Süresi

61.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 600998 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4 yıldır).

Jointown Pharmaceutical Group Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Jointown Pharmaceutical Group Co., Ltd, Annual General Meeting, May 24, 2024

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.092 (vs CN¥0.099 in 3Q 2023)

Jointown Pharmaceutical Group Co., Ltd to Report Q3, 2024 Results on Oct 29, 2024

Investor sentiment improves as stock rises 17%

Second quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.15 in 2Q 2023)

Jointown Pharmaceutical Group Co., Ltd to Report First Half, 2024 Results on Aug 27, 2024

Jointown Pharmaceutical Group Co., Ltd (SHSE:600998) announces an Equity Buyback for CNY 300 million worth of its shares.

Jointown Pharmaceutical Group Co., Ltd, Annual General Meeting, May 24, 2024

First quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.14 in 1Q 2023)

Jointown Pharmaceutical Group Co., Ltd to Report Q1, 2024 Results on Apr 27, 2024

Investor sentiment improves as stock rises 18%

Jointown Pharmaceutical Group Co., Ltd to Report Fiscal Year 2023 Results on Apr 27, 2024

Third quarter 2023 earnings released: EPS: CN¥1.16 (vs CN¥0.12 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.28 (vs CN¥0.29 in 2Q 2022)

Jointown Pharmaceutical Group Co., Ltd to Report First Half, 2023 Results on Aug 29, 2023

First quarter 2023 earnings released: EPS: CN¥0.29 (vs CN¥0.23 in 1Q 2022)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.12 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.43 (vs CN¥0.77 in 2Q 2021)

Jointown Pharmaceutical Group Co., Ltd (SHSE:600998) announces an Equity Buyback for CNY 600 million worth of its shares.

First quarter 2022 earnings released: EPS: CN¥0.23 (vs CN¥0.40 in 1Q 2021)

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.48 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.77 (vs CN¥0.37 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.40 (vs CN¥0.32 in 1Q 2020)

New 90-day high: CN¥19.23

New 90-day high: CN¥18.60

Third quarter earnings released

Jointown Pharmaceutical Group Co., Ltd. to Report Q3, 2020 Results on Oct 27, 2020

Jointown Pharmaceutical Group Co., Ltd. (SHSE:600998) intends to acquire remaining 51% stake in Hubei Buchang Jiuzhoutong Pharmaceutical Co., Ltd. from Shandong Buchang Pharmaceuticals Co., Ltd. (SHSE:603858) for CNY 21.8 million.

New 90-day low - CN¥17.39

Earnings released

New 90-day high - CN¥20.19

Jointown Pharmaceutical Group Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş